Stockreport

Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer

Rafael Holdings, Inc. Class B  (RFL) 
NASDAQ:AMEX Investor Relations: morningstar.com/funds/xnas/rytnx/quote.html
PDF Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based the [Read more]